SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the first clinical xenotransplant in its EXTEND study of the UThymoKidney™ in patients with ESRD. The transplant operation was performed at NYU Langone Health. The ongoing EXTEND study will evaluate the safety and efficacy of the UThymoKidney in ESRD patients who are not eligible for conventional allogeneic kidney transplantation or wh

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.